| 摘要 |
HIV replication inhibitors of formula R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; R2, R3, R7 and R8 are hydrogen; hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R10; C1-6alkyl optionally substituted with halo, cyano or —C(═O)R10; optionally substituted C1-6alkyl, C2-6alkenyl, or C2-6alkynyl; R4 and R9 are hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R10; cyano; —S(═O)rR10; —NH—S(═O)2R10; —NHC(═O)H; —C(═O)NHNH2; —NHC(═O)R10; Het; —Y-Het; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R5 is C2-6alkenyl or C2-6alkynyl both substituted with cyano, aminocarbonyl, mono- and di(C1-6alkyl)aminocarbonyl, aryl, pyridyl, thienyl, furanyl, or with one or two C1-6alkyloxy groups; Het; —C(═O)NR5aR5b; —CH(OR5c)R5d; X is —NR1—, —O—, —CH2—, or —S—; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
|
